--- title: "Nektar Therapeutics (NKTR) news: reverse split and class action" url: "https://aibio.space/companies/nektar-therapeutics/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "NKTR reverse split, class action and offering news: Nektar sets one-for-fifteen reverse split, effective June 8, 2025." --- NKTR Nektar Therapeutics NASDAQ · United States # Nektar Therapeutics (NKTR) news NKTR reverse split, class action and offering news Legal · 2026-09-25 ## [Jury awards Nektar $90 million in Lilly contract case; securities class action pending](https://aibio.space/news/jury-awards-nektar-90-million-lilly-contract-case-securities-class/) A federal jury found that Eli Lilly breached the implied covenant of good faith in a rezpegaldesleukin license with Nektar and awarded $90 million, according to an 8-K filed September 25, 2026. Nektar is also a defendant in a securities class action, Schramke v. Nektar Therapeutics, filed in March 2026. ## Latest Nektar Therapeutics news 1. 2026-05-08 Financings [Nektar Therapeutics sets up $150,000,000 at-the-market stock program](https://aibio.space/news/nektar-therapeutics-sets-up-150-000-000-market-stock-program/) Nektar will sell up to $150 million of stock through Guggenheim Securities and H.C. Wainwright at a 3.0% commission. The company used $208.5 million in operations in 2025, and its Phase 3 spending is set to rise. 2. 2025-06-27 Listings [Nektar Therapeutics regains compliance with Nasdaq minimum bid price rule](https://aibio.space/news/nektar-therapeutics-regains-compliance-nasdaq-minimum-bid-price-rule/) Nasdaq told Nektar on June 24, 2025 that it met the minimum bid rule after a $1.00 closing bid held for 10 consecutive business days. The 8-K gives no share price or financial figures, and the company's pipeline is still in mid-stage trials. 3. 2025-06-04 Listings [Nektar sets one-for-fifteen reverse split, effective June 8, 2025](https://aibio.space/news/nektar-sets-one-fifteen-reverse-split-effective-june-8-2025/) Nektar's board approved the split on May 23, 2025, and trading on a split-adjusted basis is set to begin June 9. The filings give no reason for the split, and a June 6 amendment raised authorized shares to 390,000,000. 4. 2024-12-02 Mergers [Nektar completes sale of Huntsville, Alabama plant to Ampersand affiliate](https://aibio.space/news/nektar-completes-sale-huntsville-alabama-plant-ampersand-affiliate/) Nektar sold the Huntsville plant, certain other related manufacturing assets and certain related liabilities to the buyer under an agreement dated November 1, 2024. ## Nektar Therapeutics at a glance - **Ticker**: NKTR - **Listing**: NASDAQ - **Country**: United States - **Cash, Jun 30, 2026**: $684.3 million ### Related companies - [Biofrontera](https://aibio.space/companies/biofrontera-bfri/) NASDAQ: BFRI - [Viridian Therapeutics](https://aibio.space/companies/viridian-therapeutics/) NASDAQ: VRDN - [Olema Pharmaceuticals](https://aibio.space/companies/olema-pharmaceuticals/) NASDAQ: OLMA - [Aquestive Therapeutics](https://aibio.space/companies/aquestive-therapeutics/) NASDAQ: AQST - [Telomir Pharmaceuticals](https://aibio.space/companies/telomir-pharmaceuticals/) NASDAQ: TELO - [Immunic](https://aibio.space/companies/immunic/) NASDAQ: IMUX - [Omeros](https://aibio.space/companies/omeros/) NASDAQ: OMER - [SIGA Technologies](https://aibio.space/companies/siga-technologies/) NASDAQ: SIGA ### Also on NASDAQ - [RenovoRx](https://aibio.space/companies/renovorx/) RNXT - [FEMASYS INC](https://aibio.space/companies/femasys/) FEMY - [Cuprina Holdings (Cayman)](https://aibio.space/companies/cuprina-cayman/) CUPR - [NRX Pharmaceuticals](https://aibio.space/companies/nrx-pharmaceuticals/) NRXP - [Gyre Therapeutics](https://aibio.space/companies/gyre-therapeutics/) GYRE - [Kura Oncology](https://aibio.space/companies/kura-oncology/) KURA ## Nektar Therapeutics annual financials | Line | FY2025 | FY2024 | |---|---|---| | Research and development | [$117.3 million](https://www.sec.gov/Archives/edgar/data/906709/000119312526104547/) | [$120.9 million](https://www.sec.gov/Archives/edgar/data/906709/000119312526104547/) | | Net income (loss) | [-$164.1 million](https://www.sec.gov/Archives/edgar/data/906709/000119312526104547/) | [-$119.0 million](https://www.sec.gov/Archives/edgar/data/906709/000119312526104547/) | | Cash from operations | [-$208.5 million](https://www.sec.gov/Archives/edgar/data/906709/000119312526104547/) | [-$175.7 million](https://www.sec.gov/Archives/edgar/data/906709/000119312526104547/) | | Cash and equivalents | [$15.1 million](https://www.sec.gov/Archives/edgar/data/906709/000119312526349805/) | [$44.3 million](https://www.sec.gov/Archives/edgar/data/906709/000119312526104547/) | | Short-term investments | [$230.6 million](https://www.sec.gov/Archives/edgar/data/906709/000119312526349805/) | [$211.0 million](https://www.sec.gov/Archives/edgar/data/906709/000119312526104547/) | Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $39.3 million, plus short-term investments of $645.1 million, $684.3 million in all. Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Nektar Therapeutics Did Nektar Therapeutics do a reverse stock split? Our latest story on this, dated Jun 4, 2025: "Nektar sets one-for-fifteen reverse split, effective June 8, 2025". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/nektar-sets-one-fifteen-reverse-split-effective-june-8-2025/). Is there a class action against Nektar Therapeutics? Our latest story on this, dated Sep 25, 2026: "Jury awards Nektar $90 million in Lilly contract case; securities class action pending". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/jury-awards-nektar-90-million-lilly-contract-case-securities-class/). Has Nektar Therapeutics raised money recently? Our latest story on this, dated May 8, 2026: "Nektar Therapeutics sets up $150,000,000 at-the-market stock program". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/nektar-therapeutics-sets-up-150-000-000-market-stock-program/). What is the ticker symbol of Nektar Therapeutics? Nektar Therapeutics trades under the ticker NKTR on NASDAQ. Where is Nektar Therapeutics listed? Nektar Therapeutics is listed on NASDAQ. Our directory also records these other listings: DUS:ITH0; FWB:ITH0; GETTEX:ITH0; HAM:ITH0; HAN:ITH0; LS:A419UB; LSE:0UNL; MUN:ITH0; SWB:ITH0; TRADEGATE:ITH0; XETR:ITH0. What is the SEC CIK of Nektar Therapeutics? The SEC Central Index Key (CIK) for Nektar Therapeutics is 906709. Its filings are on SEC EDGAR. How many shares does Nektar Therapeutics have outstanding? 34,142,994 shares as of 2026-08-07, per the cover page of its 10-Q filed 2026-08-14. Which country or territory is Nektar Therapeutics listed under? Our directory records Nektar Therapeutics under United States. What does Nektar Therapeutics do? Our directory classifies Nektar Therapeutics as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Nektar Therapeutics? The ISIN recorded for Nektar Therapeutics is US6402683063. Does aibio.space cover Nektar Therapeutics? aibio.space lists Nektar Therapeutics among 2,820 public biotech companies and publishes its news here as stories appear. Where is Nektar Therapeutics incorporated? SEC records list its state or country of incorporation as DE. Is Nektar Therapeutics profitable? Nektar Therapeutics reported a net loss of $164.1 million for the fiscal year ended Dec 31, 2025, and used $208.5 million of cash in operations, per its annual report to the SEC. How much does Nektar Therapeutics spend on research and development? $117.3 million in the fiscal year ended Dec 31, 2025, per its annual report. How much cash does Nektar Therapeutics have? $684.3 million in cash and short-term investments at Jun 30, 2026, per its 10-Q. ## Investor discussion: Nektar Therapeutics Members talk about Nektar Therapeutics (NKTR). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Nektar Therapeutics, newest first. Each line links the filing it comes from. 1. 2026-05-08 Financings Reported a financing. SEC Form 8-K (Items 1.01,5.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/906709/000119312526214976/d159808d8k.htm) 2. 2026-04-20 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/906709/000119312526164201/d138057d424b5.htm) 3. 2026-03-13 Legal Disclosed a shareholder lawsuit, subpoena or other legal matter. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/906709/000119312526104547/nktr-20251231.htm) 4. 2026-02-10 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/906709/000119312526044760/d11122d424b5.htm) 5. 2025-11-12 Financings Set up an at-the-market program to sell shares over time. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/906709/000119312525277570/d12703d424b5.htm) 6. 2025-06-30 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/906709/000119312525152827/d933055d424b5.htm) 7. 2025-06-27 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/906709/000121390025059115/ea0247333-8k_nektar.htm) 8. 2025-06-04 Listings Reported a reverse stock split. SEC Form 8-K (Items 8.01). [Source](https://www.sec.gov/Archives/edgar/data/906709/000121390025051191/ea0244011-8k_nektar.htm) 9. 2025-05-28 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07). [Source](https://www.sec.gov/Archives/edgar/data/906709/000121390025047890/ea0243394-8k_nektar.htm) 10. 2025-04-25 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/906709/000114036125015744/ny20042463x2_def14a.htm) 11. 2025-04-15 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/906709/000114036125013973/ny20042463x1_pre14a.htm) 12. 2025-04-04 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). [Source](https://www.sec.gov/Archives/edgar/data/906709/000121390025029002/ea0237178-8k_nektar.htm) 13. 2025-03-28 Financings Reported a financing. SEC Form 8-K (Items 1.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/906709/000101376225004236/ea0236055-8k_nektar.htm) 14. 2024-12-02 Mergers Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/906709/000121390024104240/ea0222533-8k_nektar.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:NKTR on TradingView](https://www.tradingview.com/symbols/NASDAQ-NKTR/). ## SEC filings and registration - **SEC name**: Nektar Therapeutics - **CIK**: 906709 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: NKTR (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**: Non-accelerated filer
Smaller reporting company - **Business address**: 455 MISSION BAY BOULEVARD SOUTH, SAN FRANCISCO, CA, 94158 - **Phone**: 4154825300 - **Shares outstanding**: 34,142,994 as of 2026-08-07 (10-Q filed 2026-08-14) - **Former names**: INHALE THERAPEUTIC SYSTEMS INC; INHALE THERAPEUTIC SYSTEMS ### Recent filings (8-K and 6-K are the company's own announcements) - [8-K](https://www.sec.gov/Archives/edgar/data/906709/000121390026105453/ea0307306-8k_nektar.htm) filed 2026-10-01 - [8-K](https://www.sec.gov/Archives/edgar/data/906709/000121390026103215/ea0306370-8k_nektar.htm) filed 2026-09-25 - [8-K](https://www.sec.gov/Archives/edgar/data/906709/000121390026098042/ea0304798-8k_nektar.htm) filed 2026-09-08 - [10-Q](https://www.sec.gov/Archives/edgar/data/906709/000119312526349805/nktr-20260630.htm) filed 2026-08-14 - [8-K](https://www.sec.gov/Archives/edgar/data/906709/000121390026089137/ea0301929-8k_nektar.htm) filed 2026-08-13 - [8-K](https://www.sec.gov/Archives/edgar/data/906709/000121390026065845/ea0293744-8k_nektar.htm) filed 2026-06-05 - [424B5](https://www.sec.gov/Archives/edgar/data/906709/000119312526215065/d267855d424b5.htm) filed 2026-05-08 - [8-K](https://www.sec.gov/Archives/edgar/data/906709/000119312526214976/d159808d8k.htm) filed 2026-05-08 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0000906709), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Nektar Therapeutics is a public biotech or pharmaceutical company listed on NASDAQ under the ticker NKTR, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Nektar Therapeutics - **Ticker**: NKTR - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US6402683063 - **Other listed symbols**: DUS:ITH0; FWB:ITH0; GETTEX:ITH0; HAM:ITH0; HAN:ITH0; LS:A419UB; LSE:0UNL; MUN:ITH0; SWB:ITH0; TRADEGATE:ITH0; XETR:ITH0 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-NKTR/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/nektar-therapeutics/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Nektar Therapeutics (NKTR) news: reverse split and class action", 2026-10-31, https://aibio.space/companies/nektar-therapeutics/